MAMITA (Mejorando la Alimentación de la Madre y su Infante a Travez de la Reducción del Azúcar) Study
To determine if a home visitation program for breastfeeding mothers affects the health of their babies.
To determine if a home visitation program for breastfeeding mothers affects the health of their babies.
To determine if MEDI8897 reduces the amount of visits to see a medical professional due to a lower respiratory tract infection caused by RSV. We will be looking at this in healthy preterm infants entering their first RSV session.
To better understand the effects of breastfeeding on infant growth and development.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
Body Composition in Newborns with MRI of Congenital Adrenal Hyperplasia (CAH).
Develop non-invasive measures to identify abnormal placental function in babies with and without congenital anomalies.
Data Collection only. By reviewing the charts of CAH infants who come to our facility for treatment, we hope to discover which treatments, all of which are standard of care, lead to better outcomes for patients (primarily in the first year of life).
The aim is to find out how overall health and wellness is related to need for pain medication after surgery.
There is currently a lack of information on critical questions surrounding laterality of ureteropelvic junction obstruction (UPJO), the difference between extrinsic and intrinsic obstruction, the utility of retrograde pyelogram, and the appropriate management for patients with concurrent UPJO and ureterovesical junction obstruction (UVJO). Therefore, we propose first a retrospective study of all pyeloplasty’s completed at CHLA for UPJO to answer some of these critical questions. The results of this study may inform future studies in this realm. We will retrospectively review all cases of pyeloplasty completed at CHLA (from 2000 through present) to identify differences in outcomes.
To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.